Neurohormonal activation in severe heart failure: Relations to patient death and the effect of treatment with flosequinan
- 30 April 2000
- journal article
- clinical trial
- Published by Elsevier in American Heart Journal
- Vol. 139 (4), 587-595
- https://doi.org/10.1016/s0002-8703(00)90035-8
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Sustained hemodynamic response to flosequinan in patients with heart failure receiving angiotensin-converting enzyme inhibitorsJournal of the American College of Cardiology, 1993
- Double-blind, placebo-controlled study of the efficacy of flosequinan in patients with chronic heart failureJournal of the American College of Cardiology, 1993
- Flosequinan, a new vasodilator: Systemic and coronary hemodynamics and neuroendocrine effects in congestive heart failureJournal of the American College of Cardiology, 1992
- Positive inotropic and lusitropic effects of intravenous flosequinan in patients with heart failureJournal of the American College of Cardiology, 1992
- Flosequinan: A vasodilator with positive inotropic activityAmerican Heart Journal, 1991
- Chronic vasodilator therapy with flosequinan in congestive heart failureClinical Cardiology, 1990
- Effect of flosequinan on exercise capacity and symptoms in severe heart failure.Heart, 1989
- Flosequinan in heart failure: acute haemodynamic and longer term symptomatic effects.BMJ, 1988
- Cumulative Hemodynamic Response to Short-Term Treatment with Flosequinan (BTS 49465), a New Direct-Acting Vasodilator Drug, in Severe Chronic Congestive Heart FailureJournal of Cardiovascular Pharmacology, 1988
- Hemodynamic effects of BTS 49465, a new long-acting systemic vasodilator drug, in patients with severe congestive heart failureAmerican Heart Journal, 1987